This webpage contains legacy information. The product is either no longer available from the supplier or has been delisted at Labome.
product summary
company name :
ACROBiosystems
product type :
protein
product name :
Human IL-1 RII / CD121b Protein, His Tag
catalog :
IL2-H4226
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
product information
company name :
ACROBiosystems
product type :
Protein
catalog :
IL2-H4226
product name :
Human IL-1 RII / CD121b Protein, His Tag
quantity :
100 ug, 1 mg
price :
260 USD, 1600 USD
quantity & price :
$260/100ug,$1600/1mg
target :
IL-1 RII
host species :
Human
By Tag :
His Tag
Research :
For Research Use Only
Source :
Human IL-1 RII, His Tag (IL2-H4226) is expressed from human 293 cells (HEK293). It contains AA Phe 14 - Glu 343 (Accession # NP_004624.1).
Endotoxin :
Less than 1.0 EU per μg by the LAL method.
Purity :
>98% as determined by SDS-PAGE.
SDS-PAGE Remark(R&NR) :
Human IL-1 RII, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 98%.
Formulation :
Lyophilized from 0.22 μm filtered solution in PBS, pH7.4. Normally trehalose is added as protectant before lyophilization. Contact us for customized product form or formulation.
Reconstitution :
Please see Certificate of Analysis for specific instructions. For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
Storage :
For long term storage, the product should be stored at lyophilized state at -20°C or lower. Please avoid repeated freeze-thaw cycles. This product is stable after storage at:
● -20°C to -70°C for 12 months in lyophilized state;
● -70℃ for 3 months under sterile conditions after reconstitution.
Background :
Interleukin-1 receptor type 2 (IL1R2) is also known as CD121 antigen-like family member B (CDw121b), IL-1 type II receptor, Interleukin-1 receptor type II, belongs to the interleukin-1 receptor family. Two distinct types of IL1 receptors which are able to bind IL1 specifically have been identified, designated as IL1RI (IL1RA) and IL1RII (IL1RB). IL1R2 is non-signaling receptor for IL1A, IL1B and IL1RN, reduces IL1B activities. Serves as a decoy receptor by competetive binding to IL1B and preventing its binding to IL1R1. IL1R2 modulates cellular response through non-signaling association with IL1RAP after binding to IL1B. IL1R2 (membrane and secreted forms) preferentially binds IL1B and poorly IL1A and IL1RN. The secreted IL1R2 recruits secreted IL1RAP with high affinity; this complex formation may be the dominant mechanism for neutralization of IL1B by secreted/soluble receptors.
References :
(1) Liu C., et al., 1996, J. Biol. Chem. 271:20965-20972.
(2) Giri J.G., et al., 1994, J. Immunol. 153:5802-5809.
(3) Symons J.A., et al., 1995, Proc. Natl. Acad. Sci. U.S.A. 92:1714-1718.
(4) Orlando S., et al., 1997, J. Biol. Chem. 272:31764-31769.
(5) Wang D., et al., 2010, Nat. Immunol. 11:905-911.
company information
ACROBiosystems
ACROBiosystems is a leading manufacturer of recombinant proteins and other critical reagents to support the development of target therapeutics, vaccines and diagnostic kits.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
Our team has worked tirelessly since the genomic sequence of SARS-CoV-2 was first published, developing a serial of critical reagents to fight COVID-19. Our team has successfully developed a new neutralizing antibody titer serologic assay kit for COVID-19 vaccine evaluation (Cat.No.TAS-K022) which really showed excellent performance.
As the emerging variants may have impacted on the development of the COVID-19 epidemic, our team is also going full steam ahead on developing a collection of spike mutants for the emerging variants of SARS-COV-2. The reagents can be used to evaluate the efficacy of the antibodies and vaccination.
We have also developed an extensive collection of recombinant proteins to support the development for bispecific antibodies, antibody drug conjugates and cell therapies.
questions and comments